Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Michael Wolff, MD

Michael Wolff, MD, Urologist, Alamance Regional Medical Center, IncUrologist
Alamance Regional Medical Center, Inc
Member of the Healthcare Council

Michael Wolff, MD, FACS is an Urologist at Alamance Regional Medical Center and a Partner at Burlington Urological Associates in North Carolina. He is board certified by the American Board of Urology with interests in prostate cancer, benign prostatic hyperplasia, kidney stones, erectile dysfunction, incontinence, and reconstructive urology. He has a particular interest in the use of high intensity focused ultrasound, or HIFU, for the treatment of prostate cancer and minimally invasive treatments of BPH (benign prostatic hyperplasia) such as TUMT and laser ablation. Dr. Wolff has consulted and performed clinical research for companies such as Merck, Pfizer, Amgen, Watson, Abbott, and USHIFU. (This is me - Update Profile)


Employment History
1988 - present Urologist
Alamance Regional Medical Center, Inc
1988 - present Partner
Burlington Urological & Associates Pa

GLG Study Groups with Michael Wolff, MD(?)

View All Study Groups with Michael Wolff, MD

GLG NewsSM Analyses by Michael Wolff, MD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Oxybutinin gel will fill a niche in OAB treatment | 10-17-2008
Analysis of: Watson Announces Positive Data for Its Investigational Oxybutynin Topical Gel for the Treatment of Overactive Bladder at SUNA's Annual Conference | www.pipelinereview.com
Author: Michael Wolff, MD, Urologist, Alamance Regional Medical Center, Inc

Ditropan XL and generic ditropan have significant side effects and oxytrol patches can cause skin irritation. These problems may be avoided with oxybutinin gel.

Intuit marketing success trumped by data | 05-30-2008
Analysis of: Mixed Outcomes in Laparoscopy for Prostates | www.nytimes.com
Author: Michael Wolff, MD, Urologist, Alamance Regional Medical Center, Inc

Robotic prostatectomy has been successfully marketed by Intuit without much clinical data backing up potential benefits.

New Drug for BPH to enter a crowded market | 02-20-2008
Analysis of: Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia | pharmalive.com
Author: Michael Wolff, MD, Urologist, Alamance Regional Medical Center, Inc

Silodosin NDA has been accepted for filing by the FDA. BPH is a very common conditin in men over the age of 50 years and this segment of the population is rapidly growing. However, many treatments are already available.

Once Daily Cialis Will Be a Niche Application | 02-06-2008
Analysis of: AMAG Pharmaceuticals, Inc. Submits New Drug Application to FDA for Ferumoxytol in Chronic Kidney Disease Patients | www.pipelinereview.com
Author: Michael Wolff, MD, Urologist, Alamance Regional Medical Center, Inc

The recent approval of once daily Cialis at low dosages further adds to the concept that spontaneity is better with respect to sexual activity and helps  Eli Lilly further distinguish its product from Viagra and Levitra.

View All GLG News SM Analyses by Michael Wolff, MD

GLG InstituteSM Seminars with Michael Wolff, MD(?)

 
Michael Wolff, MD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Michael Wolff, MD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-12-04T13:45:22.160